USANA Q4 net sales $221M, EPS $0.87; FY2023 sales -8%; FY2024 guidance $850-920M

USANA HEALTH SCIENCES INC

2023-FY EPS reported $3.30 revenue$921,010,000

Q4 net sales $221M (-3% YoY, +4% seq); diluted EPS $0.87 (+32% YoY).
FY2023 net sales $921M (-8% YoY); diluted EPS $3.30 (-8% YoY).
FY2024 guidance: net sales $850-920M, diluted EPS $2.40-3.00, down from FY2023.
Greater China active customers +5% YoY, +11% seq; North Asia net sales -10% YoY.
No share repurchases in Q4; $71M remaining authorization; cash $330M.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

USANA HEALTH SCIENCES INC updated its the fourth quarter and fiscal year ended December 30, 2023 guidance (initiated).

Period: the fourth quarter and fiscal year ended December 30, 2023
Guidance: initiated
Result: reported results

Exact text from the filing

On February 6, 2024, USANA Health Sciences, Inc. (the “Company” or “USANA”) issued a press release announcing its financial results for the fourth quarter and fiscal year ended December 30, 2023.

View on SEC.gov

Browse all earnings releases →

USANA HEALTH SCIENCES INC filing history →

Source: SEC EDGAR

accession 0001157523-24-000176

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.